Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 4/20 | 0.38 |
| ▸ | CPN1 | P15169 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1457333 | 1.00 | NOS2 (0.38) | NOS2CPN1CPB2SMN1; SMN2ITGB3 | |
| SCHEMBL4629222 | 0.82 | NOS2 (0.35) | NOS2CPN1CPB2KMT2A | |
| SCHEMBL4629218 | 0.82 | NOS2 (0.35) | NOS2CPN1CPB2KMT2A | |
| SCHEMBL7403657 | 0.81 | ALDH1A1 (0.33) | CPN1CPB2SMN1; SMN2ITGB3ITGA2B | |
| SCHEMBL7403659 | 0.81 | ALDH1A1 (0.33) | CPN1CPB2SMN1; SMN2ITGB3ITGA2B | |
| SCHEMBL23933724 | 0.78 | ALDH1A1 (0.43) | SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL385711 | 0.73 | L3MBTL1 (0.36) | SMN1; SMN2POLB | |
| SCHEMBL385712 | 0.73 | L3MBTL1 (0.36) | SMN1; SMN2POLB | |
| SCHEMBL383047 | 0.71 | L3MBTL1 (0.39) | MEN1KMT2A | |
| SCHEMBL383046 | 0.71 | L3MBTL1 (0.39) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090658-B2 | Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| EP-1664089-B1 | BASE-SUBSTITUTED BENZYLAMINE ANALOGS FOR USE AS COAGULATION FACTOR XA INHIBITORS, THE PRODUCTION AND USE THEREOF | MEDICINES CO LEIPZIG GMBH (DE) | 2011-11-16 | — | — | EP | disclosed |
| US-20110264218-A1 | INTERVERTEBRAL BODY IMPLANT, INSTRUMENT AND METHOD | SPINECRAFT, LLC, A LIMITED LIABILITY COMPANY IN DELAWARE | 2011-10-27 | — | — | US | disclosed |
| EP-2292640-A2 | Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof | The Medicines Company (Leipzig) GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| EP-1483285-B1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | CURACYTE AG (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-20070066539-A1 | Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| EP-1664089-A1 | BASE-SUBSTITUTED BENZYLAMINE ANALOGS FOR USE AS COAGULATION FACTOR XA INHIBITORS, THE PRODUCTION AND USE THEREOF | Curacyte Chemistry GmbH (DE) | 2006-06-07 | — | — | EP | disclosed |
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | CURACYTE AG (DE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005026198-A1 | BASE-SUBSTITUTED BENZYLAMINE ANALOGS FOR USE AS COAGULATION FACTOR XA INHIBITORS, THE PRODUCTION AND USE THEREOF | CURACYTE CHEMISTRY GMBH (DE) | 2005-03-24 | — | — | WO | disclosed |
| EP-1483285-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | Curacyte AG (DE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003076457-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | CURACYTE AG (DE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066539-A1 | Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof | F12, F2, F11 | NOS2 2795/4885CPN1 542/4885CPB2 20/4885 |
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | SERPINC1, TFPI, F11 | NOS2 3162/4885CPN1 432/4885CPB2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.